HER2 positive breast cancer

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  

HER2 positive breast cancer
Jan 28, 2025, 04:41 | Blog
Barbara Ewals: SIOG is proud to be a consortium partner of the Definitive Project
Barbara Ewals, Chief Executive Officer of SIOG, shared a post on LinkedIn: "Exciting news! SIOG…
Jan 19, 2025, 04:13 | Insight
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
A recent paper by Charles Geyer Jr., Chief Scientific Officer of NSABP Foundation, was mentioned…
Dec 16, 2024, 08:20 | Blog
Francisco J. Esteva: Addressing gaps in real-world oncology care through data studies
Francisco J. Esteva, Professor of Medicine at Zucker School of Medicine and Chief of Division…
Sep 23, 2024, 14:12 | Blog
Rasha Aboelhassan: Future plans for HER2-positive breast cancer patients
Rasha Aboelhassan shared on Linkedin: ''One of the best things we get from discussing experts…
Sep 7, 2024, 19:36 | Insight
A year of treatment with an ADC has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared the following on LinkedIn: “A year of treatment with a medicine…
Aug 17, 2024, 14:04 | Blog
TDxd for treating HER2-positive breast cancer with brain and/or leptomeningeal metastases
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X about recent…
Aug 4, 2024, 06:08 | Insight
New Phase 2 clinical trial for HER2-positive breast cancer led by Irene M. Kang - City of Hope Orange County
City of Hope Orange County shared on X: "City of Hope Orange County is pioneering…
Jul 29, 2024, 11:19 | Insight
Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…
Jul 27, 2024, 14:49 | Insight
Identification of Resistance Biomarkers to HER2 Inhibitors
Iván González, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X…
Jul 23, 2024, 08:25 | Blog
Paolo Tarantino: HER2: a remarkable story of precision oncology
Paolo Tarantino shared on X: "HER2: a remarkable story of precision oncology. Check this wonderful Nature…
Jul 2, 2024, 10:32 | Insight
Trastuzumab emtansine (T-DM1) is highly effective in preventing stage 1 HER2-positive breast cancer from recurring - MedEdge MEA
MedEdge MEA shared a post on LinkedIn:  . "A year of treatment with a medicine…
May 13, 2024, 07:12 | Blog
Paolo Tarantino: DESTINY-Breast06 will be presented on 6/2 at ASCO24 by my friend and mentor of many years Giuseppe Curigliano
Paolo Tarantino shared on X: "DESTINY-Breast06 will be presented on 6/2 at ASCO24 by my…
May 11, 2024, 11:39 | Blog
Julia Maués: HER2-positive, HER2-low, HER2-shy
Julia Maués, Co-Founder of Grasp Cancer, shared a post by Paolo Tarantino on X and…
Apr 28, 2024, 20:27 | Blog
Matthew Ellis: What is driving my cancer?
Matthew Ellis, Founder and CEO of the Institute for Proteogenomic Discovery, shared on LinkedIn: "What…
Mar 22, 2024, 16:49 | Insight
Guilherme Nader Marta: CLEOPATRA trial analysis shows that complete response at first imaging re-evaluation correlates with longer PFS and OS
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn: “Many patients with…
Feb 19, 2024, 18:30 | Insight
Erman Akkus: Advanced breast cancer in 2023
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "Best of the year:…
All: 16 Posts: 1 - 100
Special Coverage